X4 Pharmaceuticals, Inc. (XFOR) DCF Valuation

X4 Pharmaceuticals, Inc. (XFOR) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

X4 Pharmaceuticals, Inc. (XFOR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore the financial prospects of X4 Pharmaceuticals, Inc. (XFOR) with our user-friendly DCF Calculator! Enter your assumptions regarding growth, margins, and expenses to calculate the intrinsic value of X4 Pharmaceuticals, Inc. (XFOR) and refine your investment strategy.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 3.0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 -100 0 0 -25 -25 -25 -25 -25
EBITDA -51.7 -58.1 -85.1 -87.6 -107.5 .0 .0 .0 .0 .0
EBITDA, % 100 -1935.5 100 100 100 60 60 60 60 60
Depreciation .7 1.2 1.9 2.0 .4 .0 .0 .0 .0 .0
Depreciation, % 100 41 100 100 100 88.2 88.2 88.2 88.2 88.2
EBIT -52.4 -59.3 -87.0 -89.6 -107.9 .0 .0 .0 .0 .0
EBIT, % 100 -1976.5 100 100 100 60 60 60 60 60
Total Cash 126.2 78.7 81.8 121.7 114.2 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 2.0 .9 .7 1.2 .6
Account Receivables, % 100 30.57 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 0 100 100 100 80 80 80 80 80
Accounts Payable 2.1 3.1 4.3 7.8 8.9 .0 .0 .0 .0 .0
Accounts Payable, % 100 104.8 100 100 100 100 100 100 100 100
Capital Expenditure -.2 -1.4 -.6 -.1 -.1 .0 .0 .0 .0 .0
Capital Expenditure, % 100 -45.4 100 100 100 -9.08 -9.08 -9.08 -9.08 -9.08
Tax Rate, % -0.07715973 -0.07715973 -0.07715973 -0.07715973 -0.07715973 -0.07715973 -0.07715973 -0.07715973 -0.07715973 -0.07715973
EBITAT -56.1 -59.4 -87.0 -89.6 -108.0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -55.6 -57.4 -84.4 -84.6 -105.9 -8.4 .0 .0 .0 .0
WACC, % 7.33 7.33 7.33 7.33 7.33 7.33 7.33 7.33 7.33 7.33
PV UFCF
SUM PV UFCF -7.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -8
Net Debt -41
Equity Value 33
Diluted Shares Outstanding, MM 178
Equity Value Per Share 0.19

What You Will Get

  • Comprehensive XFOR Financials: Access to historical and projected data for precise valuation.
  • Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Real-Time Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Evaluate various scenarios to assess X4 Pharmaceuticals' future performance.
  • User-Friendly Layout: Designed for professionals but easy for newcomers to navigate.

Key Features

  • Customizable Drug Development Parameters: Adjust key metrics such as market potential, clinical trial costs, and projected timelines.
  • Instant Valuation Models: Automatically generates intrinsic value, NPV, and other financial metrics in real-time.
  • Industry-Leading Precision: Incorporates X4 Pharmaceuticals' actual performance data for accurate valuation results.
  • Effortless Scenario Testing: Evaluate various hypotheses and analyze results with ease.
  • Efficiency Booster: Avoid the hassle of constructing intricate valuation frameworks from the ground up.

How It Works

  • Download: Obtain the comprehensive Excel file featuring X4 Pharmaceuticals, Inc.'s (XFOR) financial data.
  • Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
  • Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Generate various projections and instantly compare the results.
  • Make Decisions: Leverage the valuation findings to inform your investment choices.

Why Choose X4 Pharmaceuticals, Inc. (XFOR)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Expertise: A team of seasoned professionals committed to advancing patient care.
  • Robust Pipeline: A diverse range of drug candidates in various stages of development.
  • Strong Partnerships: Collaborations with leading organizations to enhance research and development.
  • Commitment to Quality: Adherence to the highest standards in pharmaceutical manufacturing and testing.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling X4 Pharmaceuticals stock (XFOR).
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to X4 Pharmaceuticals (XFOR).
  • Consultants: Deliver professional valuation insights on X4 Pharmaceuticals (XFOR) to clients quickly and accurately.
  • Business Owners: Understand how biopharmaceutical companies like X4 Pharmaceuticals (XFOR) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to X4 Pharmaceuticals (XFOR).

What the Template Contains

  • Preloaded XFOR Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.